| Biotechnology feed | All feeds
(NASDAQ:HYTM) announced that the results of a double-blind, placebo-controlled study on the impact of the medical component of the PROMETA Treatment Program on methamphetamine dependent subjects were published in the Journal of... Medical News Today: Feb 12 2010 2:25PM Matching: flumazenil Find similar documents
(NASDAQ:HYTM) announced that the results of a double-blind, placebo-controlled study on the impact of the medical component of the PROMETA Treatment Program on methamphetamine dependent subjects were published in the Journal of... MediLexicon: Feb 12 2010 9:28AM Matching: flumazenil Find similar documents
(NASDAQ:HYTM) announced today that the results of a double-blind, placebo-controlled study on the impact of the medical component of the PROMETA Treatment Program on methamphetamine dependent subjects were published in the Journal of... News-Medical.Net: Feb 11 2010 2:08PM Matching: flumazenil Find similar documents
(NASDAQ:HYTM) announced today that the results of a double-blind, placebo-controlled study on the impact of the medical component of the PROMETA Treatment Program on methamphetamine dependent subjects were published in the Journal of... News-Medical.Net: Feb 11 2010 9:59AM Matching: flumazenil Find similar documents
Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.
All rights reserved. All other trademarks recognized. Copyright 1997-2009 - BioPortfolio Limited.
